Blood Markers for Heart Attack Risk Assessment

Primary Blood Markers for Risk Assessment

• The American College of Cardiology recommends measuring total cholesterol, LDL cholesterol, HDL cholesterol, and the total cholesterol to HDL ratio as the cornerstone of cardiovascular risk prediction in all patients 1, 2
• Apolipoprotein B (ApoB) levels ≥130 mg/dL constitute a significant risk-enhancing factor, though routine measurement is of uncertain value for widespread population screening 1, 3

Inflammatory Markers

• The European Heart Journal suggests that high-sensitivity C-reactive protein (hs-CRP) may be measured as part of refined risk assessment specifically in patients with moderate or intermediate cardiovascular risk profiles 2, 4
• hs-CRP should NOT be measured in asymptomatic low-risk individuals or already high-risk patients, as it adds minimal value at these extremes 2, 4

Clinical Application Algorithm

• The American College of Cardiology recommends calculating 10-year ASCVD risk using validated risk equations and considering hs-CRP measurement only if the patient falls into the intermediate/moderate risk category 1, 2, 4

Important Limitations and Caveats

• None of the novel markers have been evaluated as screening tests in randomized controlled trials with clinical events as outcomes, and evidence relies on observational studies and meta-analyses 1, 3
• The European Heart Journal notes that hs-CRP has multiple confounders, a narrow diagnostic window, lacks specificity, and has no dose-effect relationship between changes in hs-CRP and CVD risk 2, 4

Practical Considerations

• The ACC/AHA Work Group prioritized markers feasible for widespread use by primary care providers, considering availability, cost, assay reliability, and downstream testing risks 1, 3
• The 2013 ACC/AHA guidelines note that hs-CRP shows "some promise for clinical utility" but emphasize this is based on "limited data" 1, 3